**Table 2**. Characteristics related to the diagnosis and course of COVID-19

|  |  |
| --- | --- |
|  | All, n: 196 (% ) |
| Time from aHSCT to COVID-19 (median, IQR) days  Time after HSCT (%)  0-100 days  101-180 days  >180 days  Type of COVID-19 diagnosis (%)  PCR positive  Serology (IgM/IgG) positive    Length of PCR positivity (days, median, IQR)    Symptoms (%)  Asymptomatic  Symptomatic  Fever  Cough  URTDb symptoms (rhinitis, pharyngitis, sore throat)  LRTDc symptoms (tachypnea, dyspnea, hypoxemia)  GId  COVID-19 severity score (%)  Asymptomatic/mild  Moderate  Severe  Critical  SARS-CoV-2 variant according to GISAIDe data (%)  Alpha  Beta  Delta  Omicron  Unclassified  Thorax CT findings positivity  Laboratory findings at COVID-19 diag. (median, IQR)  WBCf (µL)  Neutrophil (µL)  Lymphocyte (µL)  Platelet (µL)  CRP (mg/L)  LDH (U/L)  DDimer (ng/mL)  Treatment (%)  Anti-viral  Anti-inflammatory  LRTDg  MIS-Ch (%)  ICUi admission (%)  Mechanical ventilation  Nonmechanical ventilation  Prognosis at 6th week of diagnosis (%)  Resolved  Death | 207 (110-341)  40 (21.7)  43 (23.4)  101 (54.9)  191 (97.4)  5 (2.6)  16 (12-27)  43 (21.9)  153 (78.1)  114 (58.2)  66 (33.7)  30 (15.3)  58 (29.6)  13 (6.6)  154 (78.5)  16 (8.2)  8 (4.1)  18 (9.2)  17 (8.7)  3 (1.5)  37 (18.9)  116 (59.2)  23 (11.7)  46 (23.5)  4.5 (2.6-6.7)  2.2 (1.1-4.1)  1.2 (0.4-2.0)  98.0 (54.7-205.2)  11.5 (1.3-39.0)  257.5 (213.2-343.5)  505.0 (310-1010.0)  33 (16.8)  27 (13.8)  58 (29.6%)  8 (4.1)  26 (13.3)  18 (9.2)  8 (4.1)  187 (95.4)  9 (4.6) |

a*HSCT*, hematopoietic stem cell transplantation; b*URTD*, upper respiratory tract disease; c*LRTD*, lower respiratory tract disease; d*GI*, gastrointestinal; e*GISAID*,Global Initiative on Sharing Avian Influenza Data; f*WBC*, white blood cell count; g*LRTD*, lower respiratory tract disease; h*MIS-C*, multisystem inflammatory syndrome in children; i*ICU*, intensive care unit